fashion -WSS

fashion

author：hotspot 2025-10-01 17:20:10 - browse：179

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Stroke rates rising, especially in working

hotspot

WSS

Medical devices makers are asking for forgiveness, not permission

Testing GLP

Adam's Take: Intra

Yancopoulos of Regeneron works to expand Dupixent success

The Bio Revolution is changing business and society

This gene therapy has record $4.25 million price. It's saved children.

focus

fashion

focus

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: Illumina, CRISPR, Regeneron

Walensky prepares to leave CDC — and Congress — behind

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Psychedelics group wrestles with new pharma identity

Guardant Health colon cancer test endorsed by FDA advisory panel

Affirmative action in medical school literally saved lives

Clinicians often fail to acknowledge the pain caused by long Covid

focus

Decentralized clinical trials need collaboration to achieve wider use

Biotech investment managers search for lucrative opportunities

Pregnancy ages women, but effects reverse after delivery

Bird flu makes raw milk dangerous to consume, mouse study finds

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

hotspot

leisure time

leisure time

focus